₹1064.8
2.47%
Low
Day's Volatility:3.54%
High
1.07%
65.00%
Low
52 Weeks Volatility:92.72%
High
27.72%
Returns % | |
1 Month Return | 8.85 % |
3 Month Return | 41.42 % |
1 Year Return | 175.51 % |
Market Stats | |
Previous Close | ₹1,071.20 |
Open | ₹1,060.00 |
Volume | 50.05K |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹5,433.03Cr |
based on 3 analysts
Based on 3 analysts offering long term price targets for Orchid Pharma Ltd. An average target of ₹1130
Source: S&P Global Market Intelligence
Organisation | Orchid Pharma Ltd |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Orchid Pharma Ltd
Orchid Pharma gains 40% in a month and delivers multibagger return of 113% to investors. The company received USFDA approval for its novel invention, Enmetazobactam, which is expected to generate global sales of $200-300 million annually. Orchid Pharma is entitled to a 6-8% royalty on worldwide sales, estimated to be around $16-25 million annually. Revenue increased by 11% QoQ and 38% YoY while net profits magnified by 45% QoQ and 262% YoY.
Orchid Pharma Ltd Shares Surge 72% in a Month - 28 Feb, 2024
Orchid Pharma Ltd shares have gained 72% in the last month and 214% in the last year, with strong revenue growth driving investor optimism. Analysts predict a 26% growth rate for the next year, outpacing the industry's predicted 12%. The high P/S ratio reflects confidence in continued revenue performance.
Orchid Pharma's Drug Receives USFDA Approval - 26 Feb, 2024
Orchid Pharma's Enmetazobactam has received approval from the USFDA for use in adults with complicated urinary tract infections (cUTI) including pyelonephritis. The drug is expected to be launched in the US within the next couple of quarters and will generate peak annual royalties of approximately $12-16 million for Orchid Pharma. Additionally, the company retains commercialisation rights for Enmetazobactam in India.
Orchid Pharma Receives USFDA Approval for Enmetazobactam Injection - 23 Feb, 2024
Chennai-based Orchid Pharma's innovative discovery, Enmetazobactam, has received USFDA approval under the NDA process. The product is expected to be launched in the US market within a couple of quarters. Orchid Pharma shares have delivered multi-bagger returns of 113.97% in the previous six months and 204.95% in a year.
Fundamentals of Orchid Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Price Rise
In the last 3 months, ORCHPHARMA stock has moved up by 41.4%
MF Holding Up
Mutual Funds have increased holdings from 9.76% to 10.40% in Dec 2023 quarter
Revenue Rich
Revenue is up for the last 3 quarters, 184.81 Cr → 228.21 Cr (in ₹), with an average increase of 10.0% per quarter
Best in 1 Year
In the last 1 year, ORCHPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
Profit Spike
Netprofit is up for the last 3 quarters, 9.4 Cr → 29.43 Cr (in ₹), with an average increase of 42.6% per quarter
Retail Holding Up
Retail Investor have increased holdings from 7.06% to 11.53% in Dec 2023 quarter
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 136.7% return, outperforming this stock by 165.9%
FII Holding Down
Foreign Institutions have decreased holdings from 8.08% to 4.14% in Dec 2023 quarter
Promoter Holding Down
Promoters have decreased holdings from 72.40% to 69.84% in Dec 2023 quarter
Orchid Pharma Ltd in the last 5 years
Lowest (-871.56x)
April 8, 2022
Today (39.94x)
April 18, 2024
Industry (61.24x)
April 18, 2024
Highest (105.04x)
September 14, 2022
Funds | Holdings |
Quant Small Cap Fund Growth Option Direct Plan | 0.92% |
Quant Multi Asset Fund Growth Option Direct Plan | 7.21% |
Invesco India Contra Fund Direct Plan Growth | 0.9% |
Nippon India Pharma Fund - Direct Plan - Growth Plan | 1.06% |
Quant Value Fund Direct Growth | 5.44% |
Investors | Holdings % | Prev. 4 periods | 3M change |
---|---|---|---|
Promoter Holdings | 69.84% | ||
Foreign Institutions | 4.14% | ||
Mutual Funds | 10.4% | 6.53 | |
Retail Investors | 11.53% | 63.40 | |
Others | 4.1% | 51.55 |
Technicals of Orchid Pharma Ltd share
News & Events of Orchid Pharma Ltd
Orchid Pharma Ltd (ORCHPHARMA) share price today is ₹1064.8
Orchid Pharma Ltd is listed on NSE
Orchid Pharma Ltd is listed on BSE
PE Ratio of Orchid Pharma Ltd is 39.94
PE ratio = Orchid Pharma Ltd Market price per share / Orchid Pharma Ltd Earnings per share
Today’s traded volume of Orchid Pharma Ltd(ORCHPHARMA) is 50.05K.
Today’s market capitalisation of Orchid Pharma Ltd(ORCHPHARMA) is ₹5433.03Cr.
Orchid Pharma Ltd(ORCHPHARMA | Price |
---|---|
52 Week High | ₹1359.95 |
52 Week Low | ₹372.65 |
Orchid Pharma Ltd(ORCHPHARMA) share price is ₹1064.8. It is down -21.70% from its 52 Week High price of ₹1359.95
Orchid Pharma Ltd(ORCHPHARMA) share price is ₹1064.8. It is up 185.74% from its 52 Week Low price of ₹372.65
Orchid Pharma Ltd(ORCHPHARMA | Returns |
---|---|
1 Day Returns | -6.4% |
1 Month Returns | 8.85% |
3 Month Returns | 41.42% |
1 Year Returns | 175.51% |